All In Biotech

Drug Trial Radar · NCT02528253

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN

Last checked: Nov 19, 2026Latest source record: Feb 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,832 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,832

Actual

Start

Aug 18, 2015

Primary completion

Oct 17, 2017

Study completion Dec 20, 2018

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Aug 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. Secondary objectives are to evaluate the long-term safety and effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. In addition, the study will evaluate the effectiveness and long term safety profile of tanezumab treatment for chronic low back pain compared to tramadol Prolonged Release (PR), a medication commonly utilized for the treatment of chronic low back pain.

Conditions

  • Low Back Pain

Interventions

  • Placebo to Week 16; tanezumab 5mg SCBiological

    Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections

  • Placebo to Week 16, tanezumab 10 mg SCBiological

    Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections

  • Tanezumab 5 mg SCBiological

    Tanezumab 5 mg SC

  • Tanezumab 10 mg SCBiological

    Tanezumab 10 mg SC

  • Tramadol PR oralBiological

    Tramadol PR oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Average Low Back Pain Intensity (LBPI) Score for Tanezumab Versus (Vs) Placebo at Week 16Time frame: Baseline, Week 16

Locations

262 sites in 9 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • Cahaba Research

    Birmingham, Alabama

  • Alabama Clinical Research, LLC

    Mobile, Alabama

  • Alabama Orthopaedic Clinic, P.C.

    Mobile, Alabama

  • Coastal Clinical Research

    Mobile, Alabama

  • Horizon Research Partners, LLC

    Mobile, Alabama

  • The Center for Clinical Trials, Inc.

    Saraland, Alabama

  • Ferguson Family Medicine

    Mesa, Arizona

  • The Pain Center of Arizona

    Phoenix, Arizona

  • Arizona Research Center

    Phoenix, Arizona

  • Valley Pain Consultants

    Scottsdale, Arizona

  • KLR Business Group dba Arkansas Clinical Research

    Little Rock, Arkansas

  • Lynn Institute of the Ozarks

    Little Rock, Arkansas

  • Primary Care of Arkansas, P.A.

    Little Rock, Arkansas

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • Core Healthcare Group

    Cerritos, California

  • eStudySite

    Chula Vista, California

  • Triwest Research Associates, LLC

    El Cajon, California

  • Research Center of Fresno, Inc.

    Fresno, California

  • Neuro-Pain Medical Center

    Fresno, California

  • Valley Research-Trials

    Fresno, California

  • Collaborative Neuroscience Network, LLC.

    Garden Grove, California

  • eStudySite

    La Mesa, California

  • Collaborative Neuroscience Network, LLC.

    Long Beach, California

  • University of Southern California

    Los Angeles, California

  • USC IDS Pharmacy

    Los Angeles, California

  • Catalina Research Institute, LLC

    Montclair, California

  • Providence Clinical Research

    North Hollywood, California

  • Northern California Research

    Sacramento, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Encompass Clinical Research

    Spring Valley, California

  • Bayview Research Group

    Valley Village, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Elite Clinical Trials, Inc.

    Wildomar, California

  • Alpine Clinical Research Center

    Boulder, Colorado

  • Mountain View Clinical Research, Inc.

    Denver, Colorado

  • Mountain View Clinical Research, Inc

    Denver, Colorado

  • New England Research Associates, LLC

    Bridgeport, Connecticut

  • My Health 1st Urgent Care

    Milford, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

Showing 40 of 262 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.